Post by icemandios on Jan 5, 2021 13:46:31 GMT
ViewRay Announces Pricing of Public Offering of Common Stock
PR Newswire
CLEVELAND , Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 10,310,000 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $50.0 million , before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,546,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.
Piper Sandler & Co. is acting as the sole book-running manager for the offering. B. Riley Securities, Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.
The offering is expected to close on or about January 7, 2021 , subject to satisfaction of customary closing conditions.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and became effective on February 7, 2019 . This offering is being made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . Alternatively, copies of the final prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis , MN55402, or by telephone at (800) 747-3924, or by email at prospectus@psc.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
PR Newswire
CLEVELAND , Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 10,310,000 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $50.0 million , before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,546,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.
Piper Sandler & Co. is acting as the sole book-running manager for the offering. B. Riley Securities, Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.
The offering is expected to close on or about January 7, 2021 , subject to satisfaction of customary closing conditions.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and became effective on February 7, 2019 . This offering is being made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . Alternatively, copies of the final prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis , MN55402, or by telephone at (800) 747-3924, or by email at prospectus@psc.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.